Journey Medical Corp (DERM) stock
DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value
$4.33−0.06 (-1.37%)
Close on Nov 13, 2026Market cap $122.21MP/E –Yield –
Journey Medical cash
Cash and short-term investments held at the end of each period.
Journey Medical's cash was $22.32M at Sep 30, 2026. For fiscal 2025 it was $24.09M, up 18.6% from the year before. The highest annual figure on record is $49.08M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.09M | +18.6% |
| FY2024 | Dec 31, 2024 | $20.31M | -26.0% |
| FY2023 | Dec 31, 2023 | $27.44M | -14.3% |
| FY2022 | Dec 31, 2022 | $32.00M | -34.8% |
| FY2021 | Dec 31, 2021 | $49.08M | +495.2% |
| FY2020 | Dec 31, 2020 | $8.25M | +71.8% |
| FY2019 | Dec 31, 2019 | $4.80M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $22.32M | -10.5% |
| Q2 FY2026 | Jun 30, 2026 | $25.64M | +26.4% |
| Q1 FY2026 | Mar 31, 2026 | $27.22M | +29.2% |
| Q4 FY2025 | Dec 31, 2025 | $24.09M | +18.6% |
| Q3 FY2025 | Sep 30, 2025 | $24.95M | +11.1% |
| Q2 FY2025 | Jun 30, 2025 | $20.29M | -15.1% |
| Q1 FY2025 | Mar 31, 2025 | $21.07M | -12.4% |
| Q4 FY2024 | Dec 31, 2024 | $20.31M | -26.0% |
| Q3 FY2024 | Sep 30, 2024 | $22.46M | -9.2% |
| Q2 FY2024 | Jun 30, 2024 | $23.91M | +173.3% |
| Q1 FY2024 | Mar 31, 2024 | $24.06M | +41.7% |
| Q4 FY2023 | Dec 31, 2023 | $27.44M | -14.3% |
| Q3 FY2023 | Sep 30, 2023 | $24.75M | -29.1% |
| Q1 FY2023 | Aug 31, 2023 | $8.75M | -77.1% |
| Q2 FY2023 | Jun 30, 2023 | $16.98M | -58.9% |
| Q4 FY2022 | Dec 31, 2022 | $32.00M | -34.8% |
| Q3 FY2022 | Sep 30, 2022 | $34.89M | +60.9% |
| Q2 FY2022 | Jun 30, 2022 | $38.14M | +213.3% |
| Q1 FY2022 | Mar 31, 2022 | $41.33M | +117.6% |
| Q4 FY2021 | Dec 31, 2021 | $49.08M | +495.2% |
| Q3 FY2021 | Sep 30, 2021 | $21.69M | +459.1% |
| Q2 FY2021 | Jun 30, 2021 | $12.18M | +153.6% |
| Q1 FY2021 | Mar 31, 2021 | $19.00M | – |
| Q4 FY2020 | Dec 31, 2020 | $8.25M | – |
| Q3 FY2020 | Sep 30, 2020 | $3.88M | – |
| Q4 FY2019 | Dec 31, 2019 | $4.80M | – |
See a number that looks wrong?